Wockhardt Limited
WOCKPHARMA
Helyezés a részvények között
#4552
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Részvényárfolyam
$20.75
Piaci kapitalizáció
$3.37B
Változás (1 nap)
-1.38%
Változás (1 év)
33.03%
Ország
IN
Kereskedés Wockhardt Limited (WOCKPHARMA)
Kategória
Healthcare
Wockhardt Limited (WOCKPHARMA) P/B aránya
P/B arány ekkor: October 2026 TTM: 6.02
Wockhardt Limited legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi könyv szerinti árfolyam aránya (P/B, TTM) 6.02. 2024 végén ez az arány 2.57 volt.
P/B arány története a(z) Wockhardt Limited esetén 2004 és 2026 között
P/B arány az év végén
| Év | P/B arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 6.02 | 16.16% |
| 2025 | 5.18 | 101.34% |
| 2024 | 2.57 | 288.97% |
| 2023 | 0.66 | -19.95% |
| 2022 | 0.83 | -43.97% |
| 2021 | 1.47 | 89.81% |
| 2020 | 0.78 | -61.99% |
| 2019 | 2.04 | -35.21% |
| 2018 | 3.15 | 21.94% |
| 2017 | 2.59 | -14.18% |
| 2016 | 3.01 | -49.76% |
| 2015 | 6.00 | 294.23% |
| 2014 | 1.52 | -82.90% |
| 2013 | 8.90 | 84.07% |
| 2012 | 4.83 | 41.70% |
| 2011 | 3.41 | 72.95% |
| 2010 | 1.97 | 55.55% |
| 2008 | 1.27 | -67.48% |
| 2007 | 3.90 | -0.89% |
| 2006 | 3.93 | -39.11% |
| 2005 | 6.46 | -5.15% |
| 2004 | 6.81 | 0.00% |
P/B arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/B arány | P/B arány különbség | Ország |
|---|---|---|---|
| 3.8424 | -36.14% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| 17.3539 | 188.42% |
US
|
|
| - | - |
IT
|
